Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis

Climacteric

Volumn 14, Issue 3, 2011, Pages 369-377

  Sanad, Z ^a   Ellakwa, H ^a   Desouky, B ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

ALENDRONATE; BONE MINERAL DENSITY; OSTEOPOROSIS; POSTMENOPAUSALWOMEN; RALOXIFENE; TOLERABILITY

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; COLECALCIFEROL; COLLAGEN TYPE 1; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGASTRIC PAIN; FEMALE; FEMUR NECK; HEARTBURN; HIP; HOT FLUSH; HUMAN; LIPID METABOLISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA;

AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; CHOLESTEROL, HDL; COLLAGEN TYPE I; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FEMUR NECK; HUMANS; LIPID METABOLISM; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; RALOXIFENE; TREATMENT OUTCOME;

EID: 79956093163     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.537408     Document Type: Article

References (35)

1. NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001;285:785-95
2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
3. Ensrud KE, Thompson DE, Cauley JA, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241-9 (Pubitemid 30164205)
4. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-73 (Pubitemid 39665705)
5. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6 (Pubitemid 32268819)
6. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112:281-9 (Pubitemid 34219441)
7. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289: 2673-84 (Pubitemid 37430138)
8. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523-34 (Pubitemid 36951364)
9. Black DM, Thompson DE, Bauer DC, et al. Fracutre risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24 (Pubitemid 32055362)
10. Levis S, Quandt SA, Thompson D, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002;50:409-15 (Pubitemid 34229393)
11. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11:83-91 (Pubitemid 30099515)
12. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52 (Pubitemid 29483192)
13. Chesnut 3rd CH, Silverman SL, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109:267-76
14. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. JAMA 1999;282:637-45 (Pubitemid 29384151)
15. Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50
16. EviöS, Tiitinen A, Laitinen K, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004;89:626-31 (Pubitemid 38269869)
17. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26 (Pubitemid 28163165)
18. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85:720-6 (Pubitemid 32273660)
19. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92 (Pubitemid 36121052)
20. Evista (raloxifene hydrochloride) Prescribing Information. Physicians' Desk Reference, 56th edn. Montvale, NJ: Medical Economics Company, Inc, 2002:1915-19
21. Fosamax (alendronate sodium) Prescribing Information. Physicians' Desk Reference, 56th edn. Montvale, NJ: Medical Economics Company, Inc, 2002:2095-102
22. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial). Int J Intern Med 2004;255:503-11 (Pubitemid 38446364)
23. Lufkin EG, Sarkar S, Kulkarni PM, et al. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rational for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin 2004;20:351-7 (Pubitemid 38339175)
24. Luckey M, Kagan R, Greenspan S, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004;11:405-15 (Pubitemid 40362164)
25. Iwamoto J, Sato Y, Uzawa M, et al. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J 2008;49:119-28 (Pubitemid 351513654)
26. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86:1890-7 (Pubitemid 32472892)
27. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-81 (Pubitemid 30646926)
28. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in the incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87: 1586-92 (Pubitemid 34615244)
29. Kanis JA, Oden A, Johnell O, et al. Uncertain future of trials in osteoporosis. Osteoporosis Int 2002;13:443-9 (Pubitemid 34742201)
30. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005;80:379-88 (Pubitemid 40316301)
31. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202 (Pubitemid 32269244)
32. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998;128:253-61 (Pubitemid 28090755)
33. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence? Mayo Clin Proc 2002;77:1031-43
34. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7 (Pubitemid 27510100)
35. Greendale GA, Wells B, Marcus R, Barrett-Connor E. How many women lose bone mineral density while taking hormone replacement therapy? Results from the postmenopausal Estrogen/ Progestin Interventions Trial. Arch Intern Med 2000;160:3065-71